MacroGenics Provides Update on Corporate Progress and 2017 Financial Results

Pharmaceutical Investing

MacroGenics (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided a corporate progress update and reported financial results for the year ended December 31, 2017. As quoted in the press release: “We have had multiple advances in our portfolio of product candidates recently,” …

MacroGenics (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided a corporate progress update and reported financial results for the year ended December 31, 2017.

As quoted in the press release:

“We have had multiple advances in our portfolio of product candidates recently,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “In addition to margetuximab passing an interim futility analysis for the SOPHIA Phase 3 metastatic breast cancer study, a combination of margetuximab with an anti-PD-1 agent has shown encouraging activity in the treatment of gastric cancer patients in a Phase 2 study. Furthermore, we continue to enroll relapsed/refractory acute myeloid leukemia (AML) patients in the flotetuzumab dose expansion study following the promising results that were presented at recent medical conferences. As we continue to advance these and our other candidates, we look forward to presenting additional data in 2018 and defining future development strategies across our portfolio.”

Click here to read the full press release.

The Conversation (0)
×